Learn More
BACKGROUND Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primitive CML cells, but the effect of the interaction complex on the response to ABL and JAK2 inhibitors is unknown. METHODS(More)
versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up Despite their efficacy in inducing deep and durable responses in chronic phase (CP) chronic myeloid leukaemia (CML) patients, BCR-ABL1 tyrosine kinase inhibitors (TKI) do not eradicate leukaemia stem cells (LSC), as proven by the persistence of BCR-ABL1+(More)
BACKGROUND Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma (HGSC). METHODS Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy(More)
  • 1